Navigation Links
Alimera Sciences Reports Fourth Quarter 2012 Financial Results
Date:3/21/2013

ATLANTA, March 21, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter ended December 31, 2012.

"We are about to begin the commercial launch of ILUVIEN®.  Product is in our European warehouse, and our distribution channels and commercial infrastructure are well positioned," said Dan Myers , president and chief executive officer of Alimera Sciences. "The training of our sales force has been completed and our teams are currently on the ground in Germany and the UK driving demand for ILUVIEN.  We will begin shipping as soon as we receive a required acceptance from the Medicine and Health products Regulatory Agency, on the intended commercial batch size.  Based on the increasing positive feedback we continue to receive, we believe that ophthalmologists in Europe are eager to prescribe ILUVIEN for their chronic DME patients who are considered insufficiently responsive to available therapies."

Market Access Update On January 23, 2013, Alimera announced that it had received final published guidance from the UK's National Institute of Health and Clinical Excellence (NICE), indicating that ILUVIEN is not a cost-effective treatment for chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. In response to this, Alimera submitted a simple patient access scheme (PAS) for ILUVIEN to the Patient Access Schemes Liaison Unit. The PAS has been agreed to by the UK's Department of Health and is now under consideration by NICE for inclusion in its rapid review facility. Under this facility, the Appraisal Commi
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
2. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
3. Alimera Sciences Names European Management Team
4. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
5. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
6. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
7. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
8. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
9. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
10. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
11. PointCross Life Sciences SENDBox and SEND-as-a-Service Prepare Pharma Companies to Comply with the FDAs Upcoming e-Data Submission Mandate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  MiMedx Group, Inc. (NASDAQ: MDXG ), an ... and bioimplants processed from human amniotic membrane, announced today its ... Highlights include: , Revenue exceeds upper end ... $25.6 million , Quarter-over-quarter revenue grew ... increases 181% over Q2 2013 and 40% sequentially over Q1 ...
(Date:7/28/2014)... , July 28, 2014   Stone & ... of off-label marketing and fraud claims between the ... Solutions, Inc. ("VSI").  The settlement covers fraud in ... for endovenous laser ablation of varicose veins for ... firm with a history of representing whistleblowers in ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire-iReach/ -- June 28 th , ... which has developed the AMAS cancer test, is making its ... To date, the test, which is a serum-based in vitro ... emerging as a significant tool in the fight against cancer ... With an estimated 17 million cancer survivors in the ...
Breaking Medicine Technology:MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:7/28/2014)... Anapolis, MD (PRWEB) July 28, 2014 Evolve ... July 16, 2014, offering its members virtual visits and dramatic ... care. , Some estimates state that as many as ... conducted virtually. “Imagine not having to leave your office or ... on your blood pressure or cholesterol,” CEO and Founder Michael ...
(Date:7/28/2014)... 28, 2014 FAA-certified medical exams ... airplane, helicopter, gyroplan or airship, and should be completed ... balloons and gliders are exempt from the medical certificate ... is to alert potential pilots and contractors of any ... detecting these conditions early, the physicians at Healthpointe ...
(Date:7/28/2014)... The “Tissue Diagnostics Market by ... & Workflow, Special Staining), Disease (Breast Cancer, ... Cell Lung Cancer and Others), Product (Instruments ... Laboratories, Contract Research Organizations and Others) & ... & RoW) - Trends & Forecast to ...
(Date:7/28/2014)... New York, NY (PRWEB) July 28, 2014 ... tickets for the Guinness International Champions Cup Match between ... new Yankee Stadium in the Bronx has hosted countless big ... have the charm and history of the original Yankee Stadium, ... events in the New York City metro area. , ...
(Date:7/28/2014)... July 29, 2014 “China Surgical ... data on the China Surgical Generators market. The ... volume (in units) and average prices (in US ... Generators, Ultrasonic Generators and Argon Plasma Coagulation Generators. ... distribution shares data for each of these market ...
Breaking Medicine News(10 mins):Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 3Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 4Health News:Healthpointe Invites All Aspiring Pilots to Complete an FAA Certified Exam 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4
... 2011. Researchers from the University of Maryland School of Medicine ... of exercise and computerized memory training to see if those ... The type of memory that will be examined is known ... and use it in a new way. Many ...
... (DECEMBER 12, 2011) Autism Speaks North America,s ... National Institutes of Health (NIH) in announcing the addition ... a data federation site for the National Database for ... will help create the largest multidisciplinary source of autism ...
... and lethal of all human brain tumors that originate ... followed by both radiation therapy and chemotherapy with temozolomide. ... temozolomide. A team of researchers led by Sameer Agnihotri, ... that the protein APNG can contribute to GBM resistance ...
... - Researchers from Boston University School of Medicine (BUSM) ... receptor (A2bAR) as a possible new therapeutic target against ... cholesterol. The findings, which appear on-line in Circulation ... is a metabolite produced naturally by cells at low ...
... New research from the laboratory of Dr. Elizabeth Leadbetter at ... of vaccines. Dr. Leadbetter,s lab has discovered new properties of ... for enhancing protection against a number of different infections. This ... of the journal Nature Immunology (Vol. 13, pp. ...
... by blocking the export of key control molecules from ... treatment for chronic lymphocytic leukemia (CLL) and other incurable ... at the Ohio State University Comprehensive Cancer Center ... Research Institute (OSUCCC James)., The agent, called KPT-SINE, ...
Cached Medicine News:Health News:Exercise/memory research for Parkinson's 2Health News:Exercise/memory research for Parkinson's 3Health News:Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research 2Health News:Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research 3Health News:Researchers identify agent responsible for protection against early stages of atherosclerosis 2Health News:Trudeau Institute announces latest discovery in vaccine development 2Health News:Trudeau Institute announces latest discovery in vaccine development 3Health News:Novel export-inhibitor shows promise for treating CLL 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: